Skip to content
Triangle logo TriangleGet started
← recurrent Salivary Gland Cancer

NCT00859937 · STUDY IN CONTEXT

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.

There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.

→

primary · POSTED

Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.

There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.

→

secondary · POSTED

Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.

There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.

→

secondary · POSTED

Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests. The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test. The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival.

Biomarkers not done due to insufficient clinical responses thus making the biomarker analysis scientifically untenable.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-salivary-gland-cancer-recurrent-79ac7906
nct id
NCT00859937
trial label
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
applicability
unclear
applicability note
Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
4
harms Count
2
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0000
    source section id
    NCT00859937-om-0000
    source outcome index
    0
    endpoint
    Response Rate
    endpoint definition
    Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
    time origin
    Up to 2 months
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0001
    source section id
    NCT00859937-om-0001
    source outcome index
    1
    endpoint
    Progression-free Survival
    endpoint definition
    Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.
    time origin
    up to 5 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0002
    source section id
    NCT00859937-om-0002
    source outcome index
    2
    endpoint
    Overall Survival
    endpoint definition
    Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.
    time origin
    Up to 5 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0003
    source section id
    NCT00859937-om-0003
    source outcome index
    3
    endpoint
    Changes in Laboratory Correlates
    endpoint definition
    Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests. The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test. The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival.
    time origin
    Baseline and 4 weeks
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Biomarkers not done due to insufficient clinical responses thus making the biomarker analysis scientifically untenable.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Adenoid Cystic Carcinoma
    regimen
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    40
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Non Adenoid Cystic Carcinoma
    regimen
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    14
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Adenoid Cystic Carcinoma
    regimen
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    40
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Non Adenoid Cystic Carcinoma
    regimen
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    14
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0001#groups/OG001
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Adenoid Cystic Carcinoma
    regimen
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    40
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0002#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Non Adenoid Cystic Carcinoma
    regimen
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    14
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0002#groups/OG001
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Adenoid Cystic Carcinoma
    regimen
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0003#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    outcome key
    om-0003
    arm key
    OG001
    arm label
    Non Adenoid Cystic Carcinoma
    regimen
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00859937-om-0003#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    harm key
    EG000
    source section id
    NCT00859937-ae
    event group key
    EG000
    event group label
    Adenoid Cystic Carcinoma
    serious affected
    12
    serious at risk
    40
    other affected
    39
    other at risk
    40
    frequency threshold
    5
    collection period
    Up to 5 years
    event definition
    All serious adverse events were reported. Other adverse events occurring in ≥5% of the study subjects were reported.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-salivary-gland-cancer-recurrent-79ac7906
    nct id
    NCT00859937
    harm key
    EG001
    source section id
    NCT00859937-ae
    event group key
    EG001
    event group label
    Non Adenoid Cystic Carcinoma
    serious affected
    8
    serious at risk
    14
    other affected
    13
    other at risk
    14
    frequency threshold
    5
    collection period
    Up to 5 years
    event definition
    All serious adverse events were reported. Other adverse events occurring in ≥5% of the study subjects were reported.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice